TNF and rheumatoid arthritis: Our results present a comprehensive overview of the alterations in the composition of the T-cell subset in RA patients on long-term anti-TNF or IL-6R blocker therapy with a focus on changes in the naive/memory subtypes, the most important effector pathways (Th1, Th2, Th17, and Treg), as well as various activation markers (CD25, CD69, and HLA-DR).